Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.

Sambandam V, Frederick MJ, Shen L, Tong P, Rao X, Peng S, Singh R, Mazumdar T, Huang C, Li Q, Pickering CR, Myers JN, Wang J, Johnson FM.

Clin Cancer Res. 2019 Jun 1;25(11):3329-3340. doi: 10.1158/1078-0432.CCR-18-3276. Epub 2019 Feb 15.

PMID:
30770351
2.

Variations in HPV function are associated with survival in squamous cell carcinoma.

Gleber-Netto FO, Rao X, Guo T, Xi Y, Gao M, Shen L, Erikson K, Kalu NN, Ren S, Xu G, Fisch KM, Akagi K, Seiwert T, Gillison M, Frederick MJ, Johnson FM, Wang J, Myers JN, Califano J, Skinner HD, Pickering CR.

JCI Insight. 2019 Jan 10;4(1). pii: 124762. doi: 10.1172/jci.insight.124762. [Epub ahead of print]

3.

Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N.

Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035.

4.

CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition.

Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwood AB, Piwnica-Worms H, Schlacher K, Frederick MJ, Myers JN.

Cancer Res. 2018 Feb 1;78(3):781-797. doi: 10.1158/0008-5472.CAN-17-2802. Epub 2017 Dec 11.

5.

Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.

Kalu NN, Mazumdar T, Peng S, Shen L, Sambandam V, Rao X, Xi Y, Li L, Qi Y, Gleber-Netto FO, Patel A, Wang J, Frederick MJ, Myers JN, Pickering CR, Johnson FM.

Oncotarget. 2017 Sep 21;8(49):86369-86383. doi: 10.18632/oncotarget.21174. eCollection 2017 Oct 17.

6.

Contrafreeloading in Rats Is Adaptive and Flexible: Support for an Animal Model of Compulsive Checking.

Frederick MJ, Cocuzzo SE.

Evol Psychol. 2017 Oct-Dec;15(4):1474704917735937. doi: 10.1177/1474704917735937.

PMID:
29073770
7.

Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.

Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, Wang J, Frederick MJ, Johnson F, Gleber-Netto FO, Fu S, Kimmel M, Wang J, Hittelman WN, Pickering CR, Myers JN, Osman AA.

Clin Cancer Res. 2017 Nov 1;23(21):6541-6554. doi: 10.1158/1078-0432.CCR-17-0947. Epub 2017 Aug 8.

8.

Chest Surgery in Female to Male Transgender Individuals.

Frederick MJ, Berhanu AE, Bartlett R.

Ann Plast Surg. 2017 Mar;78(3):249-253. doi: 10.1097/SAP.0000000000000882.

PMID:
27845966
9.

New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development.

Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN Jr, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P.

Cancer Prev Res (Phila). 2015 Nov;8(11):1027-35. doi: 10.1158/1940-6207.CAPR-14-0179. Epub 2015 Sep 4.

10.

Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.

Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, Skinner HD, Johnson FM, Myers JN, Osman AA.

Clin Cancer Res. 2015 Nov 1;21(21):4831-44. doi: 10.1158/1078-0432.CCR-15-0279. Epub 2015 Jun 29.

11.

Nipple-sparing mastectomy in patients with previous breast surgery: comparative analysis of 775 immediate breast reconstructions.

Frederick MJ, Lin AM, Neuman R, Smith BL, Austen WG Jr, Colwell AS.

Plast Reconstr Surg. 2015 Jun;135(6):954e-962e. doi: 10.1097/PRS.0000000000001283.

PMID:
26017611
12.

Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.

Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G.

Cell Rep. 2015 Apr 28;11(4):577-91. doi: 10.1016/j.celrep.2015.03.055. Epub 2015 Apr 16.

13.

Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients.

Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Alves MO, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, Licitra L, Bossi P, Kimmel M, Frederick MJ, Lichtarge O, Myers JN.

Cancer Res. 2015 Apr 1;75(7):1205-15. doi: 10.1158/0008-5472.CAN-14-2729. Epub 2015 Feb 17.

14.

Acute hypertensive crisis secondary to pheochromocytoma during elective cosmetic surgery.

Frederick MJ, Colwell AS.

Plast Reconstr Surg. 2015 Jan;135(1):238e-9e. doi: 10.1097/PRS.0000000000000784. No abstract available.

PMID:
25539346
15.

Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.

Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN.

Mol Cancer Ther. 2015 Feb;14(2):608-19. doi: 10.1158/1535-7163.MCT-14-0735-T. Epub 2014 Dec 10.

16.

Mutational landscape of aggressive cutaneous squamous cell carcinoma.

Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, Yu J, Muzny DM, Doddapaneni H, Shinbrot E, Covington KR, Zhang J, Seth S, Caulin C, Clayman GL, El-Naggar AK, Gibbs RA, Weber RS, Myers JN, Wheeler DA, Frederick MJ.

Clin Cancer Res. 2014 Dec 15;20(24):6582-92. doi: 10.1158/1078-0432.CCR-14-1768. Epub 2014 Oct 10.

17.

Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers.

Pickering CR, Zhang J, Neskey DM, Zhao M, Jasser SA, Wang J, Ward A, Tsai CJ, Ortega Alves MV, Zhou JH, Drummond J, El-Naggar AK, Gibbs R, Weinstein JN, Wheeler DA, Wang J, Frederick MJ, Myers JN.

Clin Cancer Res. 2014 Jul 15;20(14):3842-8. doi: 10.1158/1078-0432.CCR-14-0565. Epub 2014 May 29.

18.

Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer.

Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu VE, Sidransky D.

Epigenetics. 2014 Jul;9(7):1031-46. doi: 10.4161/epi.29025. Epub 2014 May 1.

19.

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.

Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN Jr, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN.

Head Neck. 2014 Nov;36(11):1547-54. doi: 10.1002/hed.23499. Epub 2014 Mar 20.

20.

Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.

Gadhikar MA, Sciuto MR, Alves MV, Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN, Frederick MJ.

Mol Cancer Ther. 2013 Sep;12(9):1860-73. doi: 10.1158/1535-7163.MCT-13-0157. Epub 2013 Jul 9.

21.

CT imaging correlates of genomic expression for oral cavity squamous cell carcinoma.

Pickering CR, Shah K, Ahmed S, Rao A, Frederick MJ, Zhang J, Unruh AK, Wang J, Ginsberg LE, Kumar AJ, Myers JN, Hamilton JD.

AJNR Am J Neuroradiol. 2013 Sep;34(9):1818-22. doi: 10.3174/ajnr.A3635. Epub 2013 Jun 13.

22.

Src inhibitors in suppression of papillary thyroid carcinoma growth.

Henderson YC, Toro-Serra R, Chen Y, Ryu J, Frederick MJ, Zhou G, Gallick GE, Lai SY, Clayman GL.

Head Neck. 2014 Mar;36(3):375-84. doi: 10.1002/hed.23316. Epub 2013 Jun 1.

23.

Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.

Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, Zweidler-McKay PA, Wu X, El-Naggar AK, Weinstein JN, Wang J, Muzny DM, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ.

Cancer Discov. 2013 Jul;3(7):770-81. doi: 10.1158/2159-8290.CD-12-0537. Epub 2013 Apr 25.

24.

Reverse phase protein microarrays and their utility in drug development.

Sereni MI, Pierobon M, Angioli R, Petricoin EF 3rd, Frederick MJ.

Methods Mol Biol. 2013;986:187-214. doi: 10.1007/978-1-62703-311-4_13.

PMID:
23436414
25.

Establishment and characterization of novel cell lines from sinonasal undifferentiated carcinoma.

Takahashi Y, Kupferman ME, Bell D, Jiffar T, Lee JG, Xie TX, Li NW, Zhao M, Frederick MJ, Gelbard A, Myers JN, Hanna EY.

Clin Cancer Res. 2012 Nov 15;18(22):6178-87. doi: 10.1158/1078-0432.CCR-12-1876. Epub 2012 Oct 2.

27.

Lessons learned from next-generation sequencing in head and neck cancer.

Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, Agrawal N.

Head Neck. 2013 Mar;35(3):454-63. doi: 10.1002/hed.23100. Epub 2012 Aug 21. Review.

28.

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.

Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN.

Science. 2011 Aug 26;333(6046):1154-7. doi: 10.1126/science.1206923. Epub 2011 Jul 28.

29.

Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.

Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W, Myers JN.

Cancer. 2011 Jul 1;117(13):2926-38. doi: 10.1002/cncr.25868. Epub 2011 Jan 10.

30.

Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF 3rd, Calvert VS, Fodale V, Wang J, Weber RS.

Am J Pathol. 2011 Feb;178(2):548-71. doi: 10.1016/j.ajpath.2010.10.044.

31.

Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.

Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL, Galer CE, Henderson YC, Jasser SA, Schwartz DL, Bankson JA, Myers JN, Lai SY.

Clin Cancer Res. 2011 Apr 15;17(8):2281-91. doi: 10.1158/1078-0432.CCR-10-2762. Epub 2011 Jan 10.

32.

Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.

Sano D, Fooshee DR, Zhao M, Andrews GA, Frederick MJ, Galer C, Milas ZL, Morrow PK, Myers JN.

Head Neck. 2011 Mar;33(3):349-58. doi: 10.1002/hed.21455.

33.

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.

Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL.

Mol Cancer Ther. 2010 Jul;9(7):1968-76. doi: 10.1158/1535-7163.MCT-10-0062. Epub 2010 Jun 29.

34.

Long-term renal function and cardiovascular disease risk in obese kidney donors.

Tavakol MM, Vincenti FG, Assadi H, Frederick MJ, Tomlanovich SJ, Roberts JP, Posselt AM.

Clin J Am Soc Nephrol. 2009 Jul;4(7):1230-8. doi: 10.2215/CJN.01350209. Epub 2009 May 14.

35.

CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.

Augsten M, Hägglöf C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick MJ, Borg A, Micke P, Egevad L, Ostman A.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3414-9. doi: 10.1073/pnas.0813144106. Epub 2009 Feb 13.

36.

Potent and broad-spectrum antimicrobial activity of CXCL14 suggests an immediate role in skin infections.

Maerki C, Meuter S, Liebi M, Mühlemann K, Frederick MJ, Yawalkar N, Moser B, Wolf M.

J Immunol. 2009 Jan 1;182(1):507-14.

37.

LBP-1b, LBP-9, and LBP-32/MGR detected in syncytiotrophoblasts from first-trimester human placental tissue and their transcriptional regulation.

Henderson YC, Frederick MJ, Wang MT, Hollier LM, Clayman GL.

DNA Cell Biol. 2008 Feb;27(2):71-9.

PMID:
18004979
38.

Hybrid microstructures from aligned carbon nanotubes and silica particles.

Agrawal S, Kumar A, Frederick MJ, Ramanath G.

Small. 2005 Aug;1(8-9):823-6. No abstract available.

PMID:
17193532
39.

Human LBP-32/MGR is a repressor of the P450scc in human choriocarcinoma cell line JEG-3.

Henderson YC, Frederick MJ, Jayakumar A, Choi Y, Wang MT, Kang Y, Evans R, Spring PM, Uesugi M, Clayman GL.

Placenta. 2007 Feb-Mar;28(2-3):152-60. Epub 2006 May 30.

PMID:
16730372
40.

Consequences of C-terminal domains and N-terminal signal peptide deletions on LEKTI secretion, stability, and subcellular distribution.

Jayakumar A, Kang Y, Henderson Y, Mitsudo K, Liu X, Briggs K, Wang M, Frederick MJ, El-Naggar AK, Bebök Z, Clayman GL.

Arch Biochem Biophys. 2005 Mar 1;435(1):89-102.

PMID:
15680911
41.

BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells.

Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, Ioannides CG, Efferson CL, El-Naggar AK, Roberts D, Clayman GL, Frederick MJ.

Cancer Res. 2004 Nov 15;64(22):8262-70. Erratum in: Cancer Res. 2004 Dec 15;64(24):9230.

42.

Expression of LEKTI domains 6-9' in the baculovirus expression system: recombinant LEKTI domains 6-9' inhibit trypsin and subtilisin A.

Jayakumar A, Kang Y, Mitsudo K, Henderson Y, Frederick MJ, Wang M, El-Naggar AK, Marx UC, Briggs K, Clayman GL.

Protein Expr Purif. 2004 May;35(1):93-101.

PMID:
15039071
43.

Production of serpins using baculovirus expression systems.

Jayakumar A, Cataltepe S, Kang Y, Frederick MJ, Mitsudo K, Henderson Y, Crawford SE, Silverman GA, Clayman GL.

Methods. 2004 Feb;32(2):177-84.

PMID:
14698630
44.

Chemokines in cancer.

Frederick MJ, Clayman GL.

Expert Rev Mol Med. 2001 Jul 18;3(19):1-18. doi: 10.1017/S1462399401003301.

PMID:
14585143
45.

Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis.

Mitsudo K, Jayakumar A, Henderson Y, Frederick MJ, Kang Y, Wang M, El-Naggar AK, Clayman GL.

Biochemistry. 2003 Apr 8;42(13):3874-81.

PMID:
12667078
46.

Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis.

Jayakumar A, Kang Y, Frederick MJ, Pak SC, Henderson Y, Holton PR, Mitsudo K, Silverman GA, EL-Naggar AK, Brömme D, Clayman GL.

Arch Biochem Biophys. 2003 Jan 15;409(2):367-74.

PMID:
12504904
47.

Characterization of human copine III as a phosphoprotein with associated kinase activity.

Caudell EG, Caudell JJ, Tang CH, Yu TK, Frederick MJ, Grimm EA.

Biochemistry. 2000 Oct 24;39(42):13034-43.

PMID:
11041869
48.

Genomic cloning, mapping, structure and promoter analysis of HEADPIN, a serpin which is down-regulated in head and neck cancer cells.

Nakashima T, Pak SC, Silverman GA, Spring PM, Frederick MJ, Clayman GL.

Biochim Biophys Acta. 2000 Jul 24;1492(2-3):441-6.

PMID:
11004515
49.

In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue.

Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, Lewis DE, El-Naggar AK, Clayman GL.

Am J Pathol. 2000 Jun;156(6):1937-50.

50.

Expression of apoptosis-related genes in human head and neck squamous cell carcinomas undergoing p53-mediated programmed cell death.

Frederick MJ, Holton PR, Hudson M, Wang M, Clayman GL.

Clin Cancer Res. 1999 Feb;5(2):361-9.

Supplemental Content

Loading ...
Support Center